Subscribe
shutterstock_2127316712_t_schneider
T. Schneider / Shutterstock.com
5 July 2022AmericasSarah Speight

Pressure-reducing eye drop patents in dispute

Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Nicox verifies patent extension eligibility at USPTO
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Nicox verifies patent extension eligibility at USPTO
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More on this story

Americas
Nicox verifies patent extension eligibility at USPTO
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner